

## DAFTAR PUSTAKA

Abbas, A. K., et al. (2015). Cellular and Molecular IMUNOLOGY. Philadelphia, ELSEVIER.

Anwar, A. I., et al. (2016). "Effectiveness of Topical Mangosteen Pericarp Extract Against Angiogenesis in Mice Exposed to Ultra Violet B." **15**(8): 745-751.

Attiq, A., et al. (2018). "Raging the war against inflammation with natural products." **9**: 976.

Aukkanimart, R., et al. (2015). "Anthelmintic, anti-inflammatory and antioxidant effects of Garcinia mangostana extract in hamster opisthorchiasis." **154**: 5-13.

Burnet, et al. (2015). Properties and Overview of Immune Responses. Cellular and Molecular Immunology. Abbas, Lichtman and Pillai, Elsevier: 1-12.

Casale, G. P., et al. (1997). "Inflammatory response of mouse skin exposed to the very potent carcinogen dibenzo [a, l] pyrene: a model for tumor promotion." **36**(1): 71-78.

Catorce, M. N., et al. (2016). "Alpha-mangostin attenuates brain inflammation induced by peripheral lipopolysaccharide administration in C57BL/6J mice." Journal of neuroimmunology **297**: 20-27.

Caughey, G. E., et al. (2001). "Roles of cyclooxygenase (COX)-1 and COX-2 in prostanoid production by human endothelial cells: selective up-regulation of prostacyclin synthesis by COX-2." **167**(5): 2831-2838.

Chen, L., et al. (2018). "Inflammatory responses and inflammation-associated diseases in organs." **9**(6): 7204.

Choi, G., et al. (2009). "Anti-inflammatory activity of Chrysanthemum indicum extract in acute and chronic cutaneous inflammation." Journal of Pharmacology **123**(1): 149-154.



Dzoyem, J. P., et al. (2015). "Anti-inflammatory activity of benzophenone and xanthone derivatives isolated from Garcinia (Clusiaceae) species." **14**: 153-158.

Fu, Y., et al. (2014). "Immune regulation and anti-inflammatory effects of isogarcinol extracted from Garcinia mangostana L. against collagen-induced arthritis." **62**(18): 4127-4134.

Gutierrez-Orozco, F., et al. (2013). " $\alpha$ -Mangostin: anti-inflammatory activity and metabolism by human cells." **61**(16): 3891-3900.

Huang, M. T., et al. (2006). "Inhibitory effects of black tea theaflavin derivatives on 12-O-tetradecanoylphorbol-13-acetate-induced inflammation and arachidonic acid metabolism in mouse ears." **50**(2): 115-122.

Ibrahim, M. Y., et al. (2016). " $\alpha$ -Mangostin from Garcinia mangostana Linn: an updated review of its pharmacological properties." **9**(3): 317-329.

Khan, A. Q., et al. (2012). "Caffeic acid attenuates 12-O-tetradecanoyl-phorbol-13-acetate (TPA)-induced NF- $\kappa$ B and COX-2 expression in mouse skin: abrogation of oxidative stress, inflammatory responses and proinflammatory cytokine production." **50**(2): 175-183.

Khan, A. Q., et al. (2013). "Geraniol attenuates 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced oxidative stress and inflammation in mouse skin: possible role of p38 MAP Kinase and NF- $\kappa$ B." **94**(3): 419-429.

Khan, A. Q., et al. (2012). "Soy isoflavones (daidzein & genistein) inhibit 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced cutaneous inflammation via modulation of COX-2 and NF- $\kappa$ B in Swiss albino mice." **302**(2-3): 266-274.

Kumar, V., et al. (2018). ROBBINS BASIC PATHOLOGY. Philadelphia, ELSEVIER.

Kupper, T. S. and R. C. J. N. R. I. Fuhlbrigge (2004). "Immune surveillance in the skin: mechanisms and clinical consequences." **4**(3): 211.

Lee, S. H., et al. (2012). "Suppression of 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced skin inflammation in mice by transduced Tat-Annexin protein." **45**(6): 354-359.

Liu, W., et al. (2018). "Glycyrhizic acid from licorice down-regulates inflammatory responses via blocking MAPK and PI3K/Akt-dependent NF- $\kappa$ B signaling pathways in TPA-induced skin inflammation." **9**(9): 1502-1510.



Loynes, C. A., et al. (2018). "PGE2 production at sites of tissue injury promotes an anti-inflammatory neutrophil phenotype and determines the outcome of inflammation resolution in vivo." **4**(9): eaar8320.

Madsen, M., et al. (2016). "Effect of 12-O-tetradecanoylphorbol-13-acetate-induced psoriasis-like skin lesions on systemic inflammation and atherosclerosis in hypercholesterolaemic apolipoprotein E deficient mice." **BMC dermatology** **16**(1): 9.

Maione, F., et al. (2016). "Medicinal plants with anti-inflammatory activities." **30**(12): 1343-1352.

Marzaimi, I. N. and W. M. Aizat (2019). Current review on mangosteen usages in antiinflammation and other related disorders. **Bioactive Food as Dietary Interventions for Arthritis and Related Inflammatory Diseases**, Elsevier: 273-289.

Modlin, et al. (2012). Innate and Adaptive Immunity in the Skin. **Fitzpatrick's Dermatology In General Medicine**. Goldsmith, Katz, Gilchrest and Leffell, McGraw Hill: 105-126.

Mortaz, E., et al. (2018). "Update on neutrophil function in severe inflammation." **9**: 2171.

Nakatani, K., et al. (2002). "Inhibitions of histamine release and prostaglandin E2 synthesis by mangosteen, a Thai medicinal plant." **Biological and Pharmaceutical Bulletin** **25**(9): 1137-1141.

Ovalle-Magallanes, B., et al. (2017). "Medicinal properties of mangosteen (*Garcinia mangostana* L.): a comprehensive update." **109**: 102-122.

Park, S.-H., et al. (2016). "Protective effects of ginsenoside F2 on 12-O-tetradecanoylphorbol-13-acetate-induced skin inflammation in mice." **478**(4): 1713-1719.

Pasparakis, M., et al. (2014). "Mechanisms regulating skin immunity and inflammation." **14**(5): 289.

Pedraza-Chaverri, J., et al. (2008). "Medicinal properties of mangosteen (*Garcinia mangostana*)." **46**(10): 3227-3239.

Pothitirat, W., et al. (2009). "Comparison of bioactive compounds content, free radical scavenging and anti-acne inducing bacteria activities of extracts from the mangosteen fruit rind at two stages of maturity." **80**(7): 442-447.



Puteri, F. H., et al. (2019). "The comparative toxicity of xanthones and tannins in mangosteen (*Garcinia mangostana* Linn.) pericarp extract against BHK-21 fibroblast cell culture." **10**(2): 319.

Sato, H., et al. (2003). "Pharmacological Profiles of High-Concentration (20 µg/g) Tacalcitol Ointment: Effects on Cutaneous Inflammation, Epidermal Proliferation, and Differentiation in Mice." The Journal of dermatology **30**(7): 510-524.

Shih, Y.-W., et al. (2010). " $\alpha$ -Mangostin suppresses phorbol 12-myristate 13-acetate-induced MMP-2/MMP-9 expressions via  $\alpha\beta\beta$  integrin/FAK/ERK and NF- $\kappa$ B signaling pathway in human lung adenocarcinoma A549 cells." **58**(1): 31-44.

Stanley, P. L., et al. (1991). "Mouse skin inflammation induced by multiple topical applications of 12-O-tetradecanoylphorbol-13-acetate." **4**(4): 262-2.

Suttirak, W., et al. (2014). "In vitro antioxidant properties of mangosteen peel extract." **51**(12): 3546-3558.

Wahid, S. and U. A. Miskad (2016). IMUNOLOGI. Surabaya, Brilian Internasional.

Wei, W.-C., et al. (2011). "Topical application of marine briarane-type diterpenes effectively inhibits 12-O-tetradecanoylphorbol-13-acetate-induced inflammation and dermatitis in murine skin." **18**(1): 94.

Widowati, W., et al. (2016). "Anti-inflammatory effect of mangosteen (*Garcinia mangostana* L.) peel extract and its compounds in LPS-induced RAW264. 7 cells." **22**(3): 147-153.

Xie, Z., et al. (2015). "Daily consumption of a mangosteen-based drink improves in vivo antioxidant and anti-inflammatory biomarkers in healthy adults: a randomized, double-blind, placebo-controlled clinical trial." **3**(4): 342-348.

Xu, X.-T., et al. (2016). "Anti-inflammatory activity effect of 2-substituted-1, 4, 5, 6-tetrahydrocyclopenta [b] pyrrole on TPA-induced skin inflammation in mice." Bioorganic & medicinal chemistry letters **26**(21): 5334-5339.

Yasukawa, K., et al. (2009). "Relative inhibitory activity of bile acids against 12-O-tetradecanoylphorbol-13-acetate-induced inflammation, and chenodeoxycholic acid inhibition of tumour promotion in mouse skin two-stage genesis." **61**(8): 1051-1056.



Zainuddin (2014). Metodeologi Penelitian Kefarmasian dan Kesehatan. Surabaya, Airlangga University Press.

Zhu, G., et al. (2017). "12-O-Tetradecanoylphorbol-13-acetate (TPA) is anti-tumorigenic in liver cancer cells via inhibiting YAP through AMOT." *7*: 44940.

## LAMPIRAN

### 1. Mencit TPA



### 2. Mencit TPA + Base cream



3. Mencit TPA + GM 2,5%



4. Mencit TPA + GM 5%




5. Mencit TPA + GM 10%




6. Mencit TPA + GM 20%




7. Histopatologi *preliminary study* pada 6 jam setelah induksi TPA




8. Histopatologi *preliminary study* pada 12 jam setelah induksi TPA



9. Histopatologi *preliminary study* pada 24 jam setelah induksi TPA




10. Histopatologi *preliminary study* pada 48 jam setelah induksi TPA




Histopatologi *preliminary study* pada 48 jam setelah induksi TPA






12. Histopatologi Kontrol



13. Histopatologi TPA



14. Histopatologi TPA + Base cream




15. Histopatologi TPA + GM 2,5%




16. Histopatologi TPA + GM 5%



17. Histopatologi TPA + GM 10%



18. Histopatologi + TPA 20%



19. Pemeriksaan ELISA



20. Krim ekstrak kulit *Garciana mangostana*



21. Uji Normalitas

**Tests of Normality**

	Kelompok	Kolmogorov-Smirnov <sup>a</sup>			Shapiro-Wilk		
		Statistic	df	Sig.	Statistic	df	Sig.
Kadar COX-2	Kontrol/Tanpa Perlakuan	.230	5	.200*	.963	5	.827
	TPA	.197	5	.200*	.954	5	.768
	TPA + Base Cream	.264	5	.200*	.853	5	.203
	TPA + GM 2.5%	.160	5	.200*	.973	5	.894
	TPA + GM 5%	.166	5	.200*	.971	5	.882
	TPA + GM 10%	.198	5	.200*	.954	5	.767



	TPA + GM 20%	.228	5	.200*	.863	5	.240
Infiltrasi Netrofil	Kontrol/Tanpa Perlakuan	.367	5	.026	.684	5	.006
	TPA	.367	5	.026	.684	5	.006
	TPA + Base Cream	.473	5	.001	.552	5	.000
	TPA + GM 2.5%	.473	5	.001	.552	5	.000
	TPA + GM 5%	.367	5	.026	.684	5	.006
	TPA + GM 10%	.367	5	.026	.684	5	.006
	TPA + GM 20%	.473	5	.001	.552	5	.000
Ketebalan Epidermis	Kontrol/Tanpa Perlakuan	.192	5	.200*	.981	5	.940
	TPA	.181	5	.200*	.977	5	.917
	TPA + Base Cream	.272	5	.200*	.821	5	.119
	TPA + GM 2.5%	.316	5	.115	.837	5	.157
	TPA + GM 5%	.277	5	.200*	.859	5	.224
	TPA + GM 10%	.195	5	.200*	.922	5	.543
	TPA + GM 20%	.198	5	.200*	.966	5	.852
Edema	Kontrol/Tanpa Perlakuan	.	5	.	.	5	.
	TPA	.	5	.	.	5	.
	TPA + Base Cream	.	5	.	.	5	.
	TPA + GM 2.5%	.	5	.	.	5	.
	TPA + GM 5%	.	5	.	.	5	.
	TPA + GM 10%	.	5	.	.	5	.
	TPA + GM 20%	.	5	.	.	5	.
Permeabilitas Vaskular	Kontrol/Tanpa Perlakuan	.	5	.	.	5	.
	TPA	.	5	.	.	5	.
	TPA + Base Cream	.	5	.	.	5	.
	TPA + GM 2.5%	.	5	.	.	5	.
	TPA + GM 5%	.	5	.	.	5	.
	TPA + GM 10%	.	5	.	.	5	.
	TPA + GM 20%	.	5	.	.	5	.

\* This is a lower bound of the true significance.

Significance Correction



22. Uji One Way Anova Kadar COX-2 Jaringan dan Ketebalan Epidermis

ANOVA						
		Sum of Squares	df	Mean Square	F	Sig.
Kadar COX-2	Between Groups	.046	6	.008	.486	.813
	Within Groups	.444	28	.016		
	Total	.490	34			
Ketebalan Epidermis	Between Groups	39058.357	6	6509.726	8.754	.000
	Within Groups	20821.926	28	743.640		
	Total	59880.283	34			

23. Uji Kruskal-Wallis Infiltrasi Netrofil

**Test Statistics<sup>a,b</sup>**

Infiltrasi Netrofil	
Kruskal-Wallis H	27.897
Df	6
Asymp. Sig.	.000

a. Kruskal Wallis Test

b. Grouping Variable: Kelompok

24. Analisa deskriptif



### Descriptives

						95% Confidence Interval for Mean			
		N	Mean	Std. Deviation	Std. Error	Lower Bound	Upper Bound	Minimum	Maximum
Kadar COX-2	Kontrol/Tanpa Perlakuan	5	.51366	.07214	.03226	.42407	.60324	.4175	.6056
	TPA	5	.60326	.16493	.07375	.39847	.80804	.3928	.7950
	TPA + Base Cream	5	.63404	.23435	.10480	.34305	.92502	.4463	1.0116
	TPA + GM 2.5%	5	.56084	.11914	.05328	.41290	.70877	.4026	.6986
	TPA + GM 5%	5	.56376	.07853	.03512	.46624	.66127	.4526	.6556
	TPA + GM 10%	5	.59384	.01970	.00881	.56936	.61831	.5721	.6199
	TPA + GM 20%	5	.55238	.05310	.02374	.48644	.61831	.4912	.6048
	Total	35	.57454	.12002	.02028	.53331	.61576	.3928	1.0116
Infiltrasi Netrofil	Kontrol/Tanpa Perlakuan	5	1.40	.548	.245	.72	2.08	1	2
	TPA	5	3.40	.548	.245	2.72	4.08	3	4
	TPA + Base Cream	5	3.80	.447	.200	3.24	4.36	3	4
	TPA + GM 2.5%	5	2.80	.447	.200	2.24	3.36	2	3
	TPA + GM 5%	5	2.40	.548	.245	1.72	3.08	2	3
	TPA + GM 10%	5	1.40	.548	.245	.72	2.08	1	2
	TPA + GM 20%	5	1.20	.447	.200	.64	1.76	1	2
	Total	35	2.34	1.083	.183	1.97	2.71	1	4



Ketebalan Epidermis	Kontrol/Tanpa Perlakuan	5	56.571	23.765	10.628	27.062	86.080	21.613	86.413
	TPA	5	107.90	48.734	21.794	47.395	168.41	51.393	179.15
		760	487	725	74	946			7
	TPA + Base Cream	5	155.80	31.573	14.120	116.60	195.01	123.72	189.69
		740	407	057	384	096	9		0
	TPA + GM 2.5%	5	64.830	25.985	11.620	32.565	97.095	42.397	108.90
		60	298	978	59	61			1
	TPA + GM 5%	5	67.994	11.059	4.9459	54.261	81.726	52.678	77.477
		00	497	57	82	18			
	TPA + GM 10%	5	62.994	18.701	8.3635	39.773	86.215	44.999	89.408
		80	528	77	79	81			
	TPA + GM 20%	5	67.591	11.019	4.9282	53.908	81.274	54.774	84.143
		60	877	39	62	58			
	Total	35	83.385	41.966	7.0936	68.969	97.801	21.613	189.69
			34	472	29	36	33		0

## 25. Uji Post Hoc

### Multiple Comparisons

Dependent Variable	Kadar COX-2	Bonferroni	Kontrol/Tanpa Perlakuan	Mean Difference (I-J)		Sig.	95% Confidence Interval	
				Mean	Std. Error		Lower Bound	Upper Bound
				Difference (I-J)				
Kadar COX-2	2	Bonferroni	Kontrol/Tanpa Perlakuan	TPA	-.0896000	.0796058	1.000	-.355515 .176315
				TPA + Base Cream	-.1203800	.0796058	1.000	-.386295 .145535
				TPA + GM 2.5%	-.0471800	.0796058	1.000	-.313095 .218735
				TPA + GM 5%	-.0501000	.0796058	1.000	-.316015 .215815
				TPA + GM 10%	-.0801800	.0796058	1.000	-.346095 .185735



	TPA + GM 20%	-.0387200	.0796058	1.000	-.304635	.227195
TPA	Kontrol/Tanpa Perlakuan	.0896000	.0796058	1.000	-.176315	.355515
	TPA + Base Cream	-.0307800	.0796058	1.000	-.296695	.235135
	TPA + GM 2.5%	.0424200	.0796058	1.000	-.223495	.308335
	TPA + GM 5%	.0395000	.0796058	1.000	-.226415	.305415
	TPA + GM 10%	.0094200	.0796058	1.000	-.256495	.275335
	TPA + GM 20%	.0508800	.0796058	1.000	-.215035	.316795
TPA + Base Cream	Kontrol/Tanpa Perlakuan	.1203800	.0796058	1.000	-.145535	.386295
	TPA	.0307800	.0796058	1.000	-.235135	.296695
	TPA + GM 2.5%	.0732000	.0796058	1.000	-.192715	.339115
	TPA + GM 5%	.0702800	.0796058	1.000	-.195635	.336195
	TPA + GM 10%	.0402000	.0796058	1.000	-.225715	.306115
	TPA + GM 20%	.0816600	.0796058	1.000	-.184255	.347575
TPA + GM 2.5%	Kontrol/Tanpa Perlakuan	.0471800	.0796058	1.000	-.218735	.313095
	TPA	-.0424200	.0796058	1.000	-.308335	.223495
	TPA + Base Cream	-.0732000	.0796058	1.000	-.339115	.192715
	TPA + GM 5%	-.0029200	.0796058	1.000	-.268835	.262995
	TPA + GM 10%	-.0330000	.0796058	1.000	-.298915	.232915
	TPA + GM 20%	.0084600	.0796058	1.000	-.257455	.274375
TPA + GM 5%	Kontrol/Tanpa Perlakuan	.0501000	.0796058	1.000	-.215815	.316015



		TPA	-.0395000	.0796058	1.000	-.305415	.226415
		TPA + Base Cream	-.0702800	.0796058	1.000	-.336195	.195635
		TPA + GM 2.5%	.0029200	.0796058	1.000	-.262995	.268835
		TPA + GM 10%	-.0300800	.0796058	1.000	-.295995	.235835
		TPA + GM 20%	.0113800	.0796058	1.000	-.254535	.277295
	TPA + GM 10%	Kontrol/Tanpa Perlakuan	.0801800	.0796058	1.000	-.185735	.346095
		TPA	-.0094200	.0796058	1.000	-.275335	.256495
		TPA + Base Cream	-.0402000	.0796058	1.000	-.306115	.225715
		TPA + GM 2.5%	.0330000	.0796058	1.000	-.232915	.298915
		TPA + GM 5%	.0300800	.0796058	1.000	-.235835	.295995
		TPA + GM 20%	.0414600	.0796058	1.000	-.224455	.307375
	TPA + GM 20%	Kontrol/Tanpa Perlakuan	.0387200	.0796058	1.000	-.227195	.304635
		TPA	-.0508800	.0796058	1.000	-.316795	.215035
		TPA + Base Cream	-.0816600	.0796058	1.000	-.347575	.184255
		TPA + GM 2.5%	-.0084600	.0796058	1.000	-.274375	.257455
		TPA + GM 5%	-.0113800	.0796058	1.000	-.277295	.254535
		TPA + GM 10%	-.0414600	.0796058	1.000	-.307375	.224455
Tamhane	Kontrol/Tanpa Perlakuan	TPA	-.0896000	.0805076	1.000	-.515740	.336540
		TPA + Base Cream	-.1203800	.1096587	1.000	-.762526	.521766
		TPA + GM 2.5%	-.0471800	.0622897	1.000	-.343496	.249136
		TPA + GM 5%	-.0501000	.0476929	1.000	-.258252	.158052



	TPA + GM	-.0801800	.0334470	.763	-.281367	.121007
	<u>10%</u>					
	TPA + GM	-.0387200	.0400629	1.000	-.219481	.142041
	<u>20%</u>					
TPA	Kontrol/Tanpa Perlakuan	.0896000	.0805076	1.000	-.336540	.515740
	TPA + Base Cream	-.0307800	.1281581	1.000	-.615185	.553625
	TPA + GM	.0424200	.0909915	1.000	-.369899	.454739
	<u>2.5%</u>					
	TPA + GM 5%	.0395000	.0816949	1.000	-.380982	.459982
	TPA + GM	.0094200	.0742843	1.000	-.482530	.501370
	<u>10%</u>					
	TPA + GM	.0508800	.0774887	1.000	-.397862	.499622
	<u>20%</u>					
TPA + Base Cream	Kontrol/Tanpa Perlakuan	.1203800	.1096587	1.000	-.521766	.762526
	TPA	.0307800	.1281581	1.000	-.553625	.615185
	TPA + GM	.0732000	.1175713	1.000	-.518829	.665229
	<u>2.5%</u>					
	TPA + GM 5%	.0702800	.1105334	1.000	-.563203	.703763
	TPA + GM	.0402000	.1051747	1.000	-.665669	.746069
	<u>10%</u>					
	TPA + GM	.0816600	.1074619	1.000	-.587149	.750469
	<u>20%</u>					
TPA + GM 2.5%	Kontrol/Tanpa Perlakuan	.0471800	.0622897	1.000	-.249136	.343496
	TPA	-.0424200	.0909915	1.000	-.454739	.369899
	TPA + Base Cream	-.0732000	.1175713	1.000	-.665229	.518829
	<u>5%</u>					
	TPA + GM 5%	-.0029200	.0638168	1.000	-.299004	.293164
	TPA + GM	-.0330000	.0540063	1.000	-.382486	.316486
	<u>10%</u>					
	TPA + GM	.0084600	.0583354	1.000	-.298431	.315351
	<u>20%</u>					



		TPA + GM 5%	Kontrol/Tanpa Perlakuan	.0501000	.0476929	1.000	-.158052	.258252
		TPA	TPA	-.0395000	.0816949	1.000	-.459982	.380982
		TPA + Base Cream	TPA + GM 2.5%	-.0702800	.1105334	1.000	-.703763	.563203
		TPA + GM 2.5%	TPA + GM 10%	.0029200	.0638168	1.000	-.293164	.299004
		TPA + GM 10%	TPA + GM 20%	-.0300800	.0362117	1.000	-.251549	.191389
		TPA + GM 20%	TPA + GM 2.5%	.0113800	.0423984	1.000	-.183966	.206726
		TPA + GM 10%	Kontrol/Tanpa Perlakuan	.0801800	.0334470	.763	-.121007	.281367
		TPA + GM 10%	TPA	-.0094200	.0742843	1.000	-.501370	.482530
		TPA + GM 10%	TPA + Base Cream	-.0402000	.1051747	1.000	-.746069	.665669
		TPA + GM 10%	TPA + GM 2.5%	.0330000	.0540063	1.000	-.316486	.382486
		TPA + GM 10%	TPA + GM 5%	.0300800	.0362117	1.000	-.191389	.251549
		TPA + GM 10%	TPA + GM 20%	.0414600	.0253321	.975	-.099642	.182562
		TPA + GM 20%	Kontrol/Tanpa Perlakuan	.0387200	.0400629	1.000	-.142041	.219481
		TPA + GM 20%	TPA	-.0508800	.0774887	1.000	-.499622	.397862
		TPA + GM 20%	TPA + Base Cream	-.0816600	.1074619	1.000	-.750469	.587149
		TPA + GM 20%	TPA + GM 2.5%	-.0084600	.0583354	1.000	-.315351	.298431
		TPA + GM 20%	TPA + GM 5%	-.0113800	.0423984	1.000	-.206726	.183966
		TPA + GM 20%	TPA + GM 10%	-.0414600	.0253321	.975	-.182562	.099642
Infiltrasi	Bonferroni	Kontrol/Tanpa	TPA	-2.000*	.321	.000	-3.07	-.93
Netrofil		Perlakuan	TPA + Base Cream	-2.400*	.321	.000	-3.47	-1.33



	TPA + GM 2.5%	-1.400*	.321	.003	-2.47	-.33
	TPA + GM 5%	-1.000	.321	.088	-2.07	.07
	TPA + GM 10%	.000	.321	1.000	-1.07	1.07
	TPA + GM 20%	.200	.321	1.000	-.87	1.27
TPA	Kontrol/Tanpa Perlakuan	2.000*	.321	.000	.93	3.07
	TPA + Base Cream	-.400	.321	1.000	-1.47	.67
	TPA + GM 2.5%	.600	.321	1.000	-.47	1.67
	TPA + GM 5%	1.000	.321	.088	-.07	2.07
	TPA + GM 10%	2.000*	.321	.000	.93	3.07
	TPA + GM 20%	2.200*	.321	.000	1.13	3.27
	TPA + Base Cream	2.400*	.321	.000	1.33	3.47
TPA + GM 2.5%	Kontrol/Tanpa Perlakuan	2.400*	.321	.000	1.33	3.47
	TPA	.400	.321	1.000	-.67	1.47
	TPA + GM 2.5%	1.000	.321	.088	-.07	2.07
	TPA + GM 5%	1.400*	.321	.003	.33	2.47
	TPA + GM 10%	2.400*	.321	.000	1.33	3.47
	TPA + GM 20%	2.600*	.321	.000	1.53	3.67
	Kontrol/Tanpa Perlakuan	1.400*	.321	.003	.33	2.47
TPA + GM 5%	TPA	-.600	.321	1.000	-1.67	.47
	TPA + Base Cream	-1.000	.321	.088	-2.07	.07
	TPA + GM 5%	.400	.321	1.000	-.67	1.47

	TPA + GM	1.400*	.321	.003	.33	2.47
	10%					
	TPA + GM	1.600*	.321	.001	.53	2.67
	20%					
TPA + GM 5%	Kontrol/Tanpa Perlakuan	1.000	.321	.088	-.07	2.07
	TPA	-1.000	.321	.088	-2.07	.07
	TPA + Base Cream	-1.400*	.321	.003	-2.47	-.33
	TPA + GM 2.5%	-.400	.321	1.000	-1.47	.67
TPA + GM	1.000	.321	.088	-.07	2.07	
10%						
TPA + GM	1.200*	.321	.018	.13	2.27	
20%						
TPA + GM	Kontrol/Tanpa Perlakuan	.000	.321	1.000	-1.07	1.07
10%						
TPA	-2.000*	.321	.000	-3.07	-.93	
TPA + Base Cream	-2.400*	.321	.000	-3.47	-1.33	
TPA + GM 2.5%	-1.400*	.321	.003	-2.47	-.33	
TPA + GM 5%	-1.000	.321	.088	-2.07	.07	
TPA + GM	.200	.321	1.000	-.87	1.27	
20%						
TPA + GM	Kontrol/Tanpa Perlakuan	-.200	.321	1.000	-1.27	.87
20%						
TPA	-2.200*	.321	.000	-3.27	-1.13	
TPA + Base Cream	-2.600*	.321	.000	-3.67	-1.53	
TPA + GM 2.5%	-1.600*	.321	.001	-2.67	-.53	
TPA + GM 5%	-1.200*	.321	.018	-2.27	-.13	
TPA + GM	-.200	.321	1.000	-1.27	.87	
10%						



Tamhane	Kontrol/Tanpa Perlakuan	TPA	-2.000*	.346	.009	-3.51	-.49
		TPA + Base Cream	-2.400*	.316	.002	-3.80	-1.00
		TPA + GM 2.5%	-1.400*	.316	.050	-2.80	.00
		TPA + GM 5%	-1.000	.346	.350	-2.51	.51
		TPA + GM 10%	.000	.346	1.000	-1.51	1.51
		TPA + GM 20%	.200	.316	1.000	-1.20	1.60
	TPA	Kontrol/Tanpa Perlakuan	2.000*	.346	.009	.49	3.51
		TPA + Base Cream	-.400	.316	.997	-1.80	1.00
		TPA + GM 2.5%	.600	.316	.879	-.80	2.00
		TPA + GM 5%	1.000	.346	.350	-.51	2.51
		TPA + GM 10%	2.000*	.346	.009	.49	3.51
		TPA + GM 20%	2.200*	.316	.003	.80	3.60
	TPA + Base Cream	Kontrol/Tanpa Perlakuan	2.400*	.316	.002	1.00	3.80
		TPA	.400	.316	.997	-1.00	1.80
		TPA + GM 2.5%	1.000	.283	.149	-.23	2.23
		TPA + GM 5%	1.400*	.316	.050	.00	2.80
		TPA + GM 10%	2.400*	.316	.002	1.00	3.80
		TPA + GM 20%	2.600*	.283	.000	1.37	3.83
	TPA + GM 2.5%	Kontrol/Tanpa Perlakuan	1.400*	.316	.050	.00	2.80
		TPA	-.600	.316	.879	-2.00	.80



	TPA + Base	-1.000	.283	.149	-2.23	.23
	Cream					
	TPA + GM 5%	.400	.316	.997	-1.00	1.80
	TPA + GM 10%	1.400*	.316	.050	.00	2.80
	TPA + GM 20%	1.600*	.283	.010	.37	2.83
	TPA + GM 5% Kontrol/Tanpa Perlakuan	1.000	.346	.350	-.51	2.51
	TPA	-1.000	.346	.350	-2.51	.51
	TPA + Base Cream	-1.400*	.316	.050	-2.80	.00
	TPA + GM 2.5%	-.400	.316	.997	-1.80	1.00
	TPA + GM 10%	1.000	.346	.350	-.51	2.51
	TPA + GM 20%	1.200	.316	.113	-.20	2.60
	TPA + GM 10% Kontrol/Tanpa Perlakuan	.000	.346	1.000	-1.51	1.51
	TPA	-2.000*	.346	.009	-3.51	-.49
	TPA + Base Cream	-2.400*	.316	.002	-3.80	-1.00
	TPA + GM 2.5%	-1.400*	.316	.050	-2.80	.00
	TPA + GM 5%	-1.000	.346	.350	-2.51	.51
	TPA + GM 20%	.200	.316	1.000	-1.20	1.60
	TPA + GM 20% Kontrol/Tanpa Perlakuan	-.200	.316	1.000	-1.60	1.20
	TPA	-2.200*	.316	.003	-3.60	-.80
	TPA + Base Cream	-2.600*	.283	.000	-3.83	-1.37
	TPA + GM 2.5%	-1.600*	.283	.010	-2.83	-.37



			TPA + GM 5%	-1.200	.316	.113	-2.60	.20
			TPA + GM	-.200	.316	1.000	-1.60	1.20
			10%					
Ketebalan	Bonferroni	Kontrol/Tanpa	TPA	-	17.24691	.125	-	6.27539
Epidermis		Perlakuan		51.33620	5		108.9477	
				0			9	
			TPA + Base	-	17.24691	.000	-	-41.62441
			Cream	99.23600	5		156.8475	
				0*			9	
			TPA + GM	-8.259200	17.24691	1.000	-65.87079	49.35239
			2.5%		5			
			TPA + GM 5%	-	17.24691	1.000	-69.03419	46.18899
				11.42260	5			
				0				
			TPA + GM	-6.423400	17.24691	1.000	-64.03499	51.18819
			10%		5			
			TPA + GM	-	17.24691	1.000	-68.63179	46.59139
			20%	11.02020	5			
				0				
		TPA	Kontrol/Tanpa	51.33620	17.24691	.125	-6.27539	108.9477
			Perlakuan	0	5			9
			TPA + Base	-	17.24691	.203	-	9.71179
			Cream	47.89980	5		105.5113	
				0			9	
			TPA + GM	43.07700	17.24691	.392	-14.53459	100.6885
			2.5%	0	5			9
			TPA + GM 5%	39.91360	17.24691	.592	-17.69799	97.52519
				0	5			
			TPA + GM	44.91280	17.24691	.306	-12.69879	102.5243
			10%	0	5			9
			TPA + GM	40.31600	17.24691	.562	-17.29559	97.92759
			20%	0	5			
		TPA + Base	Kontrol/Tanpa	99.23600	17.24691	.000	41.62441	156.8475
			Cream	0*	5			9
			TPA	47.89980	17.24691	.203	-9.71179	105.5113
				0	5			9



	TPA + GM	90.97680	17.24691	.000	33.36521	148.5883
2.5%	0*	5				9
TPA + GM 5%	87.81340	17.24691	.000	30.20181	145.4249	9
	0*	5				
TPA + GM	92.81260	17.24691	.000	35.20101	150.4241	9
10%	0*	5				
TPA + GM	88.21580	17.24691	.000	30.60421	145.8273	9
20%	0*	5				
TPA + GM 2.5%	Kontrol/Tanpa Perlakuan	8.259200	17.24691	1.000	-49.35239	65.87079
	TPA	- 43.07700 0	17.24691 5	.392	- 100.6885 9	14.53459
TPA + Base	-	17.24691	.000	-	-	-33.36521
Cream	90.97680 0*	5		148.5883 9		
TPA + GM 5%	-3.163400	17.24691 5	1.000	-60.77499	54.44819	
TPA + GM 10%	1.835800	17.24691 5	1.000	-55.77579	59.44739	
TPA + GM 20%	-2.761000	17.24691 5	1.000	-60.37259	54.85059	
TPA + GM 5%	Kontrol/Tanpa Perlakuan	11.42260 0	17.24691 5	1.000	-46.18899	69.03419
	TPA	- 39.91360 0	17.24691 5	.592	-97.52519	17.69799
TPA + Base	-	17.24691	.000	-	-	-30.20181
Cream	87.81340 0*	5		145.4249 9		
TPA + GM 2.5%	3.163400	17.24691 5	1.000	-54.44819	60.77499	
TPA + GM 10%	4.999200	17.24691 5	1.000	-52.61239	62.61079	
TPA + GM 20%	.402400	17.24691 5	1.000	-57.20919	58.01399	



		TPA + GM	Kontrol/Tanpa	6.423400	17.24691	1.000	-51.18819	64.03499
	10%	Perlakuan			5			
		TPA	-	17.24691	.306	-	12.69879	
			44.91280	5		102.5243		
			0			9		
		TPA + Base	-	17.24691	.000	-	-35.20101	
		Cream	92.81260	5		150.4241		
			0*			9		
		TPA + GM	-1.835800	17.24691	1.000	-59.44739	55.77579	
		2.5%		5				
		TPA + GM 5%	-4.999200	17.24691	1.000	-62.61079	52.61239	
				5				
		TPA + GM	-4.596800	17.24691	1.000	-62.20839	53.01479	
		20%		5				
		TPA + GM	11.02020	17.24691	1.000	-46.59139	68.63179	
	20%	Perlakuan	0	5				
		TPA	-	17.24691	.562	-97.92759	17.29559	
			40.31600	5				
			0					
		TPA + Base	-	17.24691	.000	-	-30.60421	
		Cream	88.21580	5		145.8273		
			0*			9		
		TPA + GM	2.761000	17.24691	1.000	-54.85059	60.37259	
		2.5%		5				
		TPA + GM 5%	-.402400	17.24691	1.000	-58.01399	57.20919	
				5				
		TPA + GM	4.596800	17.24691	1.000	-53.01479	62.20839	
		10%		5				
	Tamhane	Kontrol/Tanpa	TPA	-	.827	-	72.47893	
		Perlakuan	51.33620	9		175.1513		
			0			3		
		TPA + Base	-	17.67313	.014	-	-19.88249	
		Cream	99.23600	4		178.5895		
			0*			1		
		TPA + GM	-8.259200	15.74835	1.000	-77.01288	60.49448	
		2.5%		9				



	TPA + GM 5%	-	11.72289	1.000	-72.22372	49.37852
		11.42260	0			
	0					
	TPA + GM	-6.423400	13.52453	1.000	-66.62139	53.77459
	10%		6			
	TPA + GM	-	11.71542	1.000	-71.85502	49.81462
	20%	11.02020	5			
	0					
TPA	Kontrol/Tanpa	51.33620	24.24816	.827	-72.47893	175.1513
	Perlakuan	0	9			3
	TPA + Base	-	25.96894	.910	-	73.17602
	Cream	47.89980	4		168.9756	
		0			2	
	TPA + GM	43.07700	24.69933	.947	-79.33594	165.4899
	2.5%	0	6			4
	TPA + GM 5%	39.91360	22.34888	.960	-99.14689	178.9740
		0	2			9
	TPA + GM	44.91280	23.34436	.915	-83.83590	173.6615
	10%	0	7			0
	TPA + GM	40.31600	22.34496	.957	-98.79907	179.4310
	20%	0	8			7
TPA + Base Cream	Kontrol/Tanpa	99.23600	17.67313	.014	19.88249	178.5895
	Perlakuan	0*	4			1
	TPA	47.89980	25.96894	.910	-73.17602	168.9756
		0	4			2
	TPA + GM	90.97680	18.28724	.025	10.18759	171.7660
	2.5%	0*	0			1
	TPA + GM 5%	87.81340	14.96123	.043	3.09231	172.5344
		0*	3			9
	TPA + GM	92.81260	16.41113	.021	14.20498	171.4202
	10%	0*	8			2
	TPA + GM	88.21580	14.95538	.042	3.44356	172.9880
	20%	0*	5			4
	TPA + GM	Kontrol/Tanpa	8.259200	15.74835	1.000	-60.49448
	2.5%	Perlakuan		9		77.01288



	TPA	-	24.69933	.947	-	79.33594
	43.07700	6		165.4899		
	0			4		
	TPA + Base	-	18.28724	.025	-	-10.18759
	Cream	90.97680	0		171.7660	
	0*			1		
	TPA + GM 5%	-3.163400	12.62971	1.000	-70.60925	64.28245
		2				
	TPA + GM	1.835800	14.31770	1.000	-63.10024	66.77184
	10%		1			
	TPA + GM	-2.761000	12.62278	1.000	-70.24749	64.72549
	20%		4			
	TPA + GM 5%	Kontrol/Tanpa	11.42260	11.72289	1.000	-49.37852
		Perlakuan	0	0		72.22372
	TPA	-	22.34888	.960	-	99.14689
		39.91360	2		178.9740	
		0			9	
	TPA + Base	-	14.96123	.043	-	-3.09231
	Cream	87.81340	3		172.5344	
	0*				9	
	TPA + GM	3.163400	12.62971	1.000	-64.28245	70.60925
	2.5%		2			
	TPA + GM	4.999200	9.716580	1.000	-41.56570	51.56410
	10%					
	TPA + GM	.402400	6.982122	1.000	-29.98216	30.78696
	20%					
	TPA + GM	Kontrol/Tanpa	6.423400	13.52453	1.000	-53.77459
	10%	Perlakuan		6		66.62139
	TPA	-	23.34436	.915	-	83.83590
		44.91280	7		173.6615	
		0			0	
	TPA + Base	-	16.41113	.021	-	-14.20498
	Cream	92.81260	8		171.4202	
	0*				2	
	TPA + GM	-1.835800	14.31770	1.000	-66.77184	63.10024
	2.5%		1			



	TPA + GM 5%	-4.999200	9.716580	1.000	-51.56410	41.56570
	TPA + GM 20%	-4.596800	9.707573	1.000	-51.17118	41.97758
TPA + GM 20%	Kontrol/Tanpa Perlakuan	11.02020	11.71542	1.000	-49.81462	71.85502
	TPA	-	22.34496	.957	-	98.79907
		40.31600	8		179.4310	
		0			7	
	TPA + Base Cream	-	14.95538	.042	-	-3.44356
		88.21580	5		172.9880	
		0*			4	
TPA + GM 2.5%	2.761000	12.62278	1.000	-64.72549	70.24749	
TPA + GM 5%	-.402400	6.982122	1.000	-30.78696	29.98216	
TPA + GM 10%	4.596800	9.707573	1.000	-41.97758	51.17118	

\*. The mean difference is significant at the 0.05 level.

## 26. Uji Independent Sample T-Test kadar COX-2

	Kontrol	TPA	TPA+BC	TPA+GM 2,5%	TPA+GM 5%	TPA+GM 10%	TPA+GM 20%
Kontrol		0.298	0.304	0.471	0.324	0.043	0.362
TPA			0.816	0.471	0.324	0.043	0.362
TPA+BC				0.551	0.543	0.712	0.469
TPA+GM 2,5%					0.965	0.558	0.888
TPA+GM 5%						0.430	0.795
TPA+GM 10%							0.140
TPA+GM 20%							

## 27. Uji Mann-Whitney Infiltrasi Netrofil



	Kontrol	TPA	TPA+BC	TPA+GM 2,5%	TPA+GM 5%	TPA+GM 10%	TPA+GM 20%
Kontrol	0,007	0,006	0,011	0,031	1,000	0,513	
TPA		0,221	0,093	0,031	0,007	0,006	
TPA+BC			0,015	0,011	0,006	0,005	
TPA+GM 2,5%				0,221	0,011	0,007	
TPA+GM 5%					0,031	0,014	
TPA+GM 10%							0,513
TPA+GM 20%							

## 28. Uji Independent Sample T-Test Ketebalan Epidermis

	Kontrol	TPA	TPA+BC	TPA+GM 2,5%	TPA+GM 5%	TPA+GM 10%	TPA+GM 20%
Kontrol	0.067	0.001	0.614	0.358	0.648	0.374	
TPA		0.102	0.614	0.358	0.648	0.374	
TPA+BC			0.001	0.000	0.000	0.000	
TPA+GM 2,5%				0.809	0.901	0.832	
TPA+GM 5%					0.621	0.905	
TPA+GM 10%						0.648	
TPA+GM 20%							

## 29. Uji crosstab edema

**Crosstab**

		Count									
		Kontrol/Tanpa		TPA +		Kelompok					
		Perlakuan	TPA	Base	Cream	2.5%	5%	TPA + GM	10%	TPA + GM	
Edem	Ada	0	5	5	5	5	5	5	5	5	30
a	Tidak Ada	5	0	0	0	0	0	0	0	0	5
	Total	5	5	5	5	5	5	5	5	5	35

## 30. Uji Chi-Square edema

**Chi-Square Tests**

	Value	df	Asymptotic Significance (2-sided)
Pearson Chi-Square	35.000 <sup>a</sup>	6	.000
Likelihood Ratio	28.708	6	.000
Linear-by-Linear Association	12.750	1	.000
N of Valid Cases	35		

a. 14 cells (100,0%) have expected count less than 5. The minimum expected count is ,71.

### 31. Uji crosstab permeabilitas vaskular

**Crosstab**

		Count								Total		
		Kontrol/Ta npa		TPA + Base		TPA + GM 2.5%		TPA + GM 5%		TPA + GM 10%		
		Perlakuan	TPA	Cream	Base	TPA + GM 2.5%	TPA + GM 5%	TPA + GM 10%	TPA + GM 20%	TPA + GM 10%	TPA + GM 20%	
Permeabilitas	Vaskular	Ada	0	5	5	5	5	5	5	5	5	30
Permeabilitas	Tidak		5	0	0	0	0	0	0	0	0	5
Vaskular	Ada											
	Total		5	5	5	5	5	5	5	5	5	35

### 32. Uji Chi-Square permeabilitas vaskular

**Chi-Square Tests**

	Value	df	Asymptotic Significance (2- sided)
Pearson Chi-Square	35.000 <sup>a</sup>	6	.000
Likelihood Ratio	28.708	6	.000
Linear-by-Linear Association	12.750	1	.000
N of Valid Cases	35		

a. 14 cells (100,0%) have expected count less than 5. The minimum expected count is ,71.